T cell progenitor production method

The method of culturing CD34+ cells with SR1 and UM171, along with other factors, efficiently produces T progenitor cells, addressing the inefficiencies in current production methods and enabling effective T cell recovery and cancer treatment.

WO2024248141A1PCT designated stage expired Publication Date: 2024-12-05KYOTO UNIV +1
View PDF 20 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/020073
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-02
Filing Date
2024-05-31
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Current methods for producing T progenitor cells are inefficient, and there is a need for an industrial method that can produce these cells with high yield for therapeutic applications, particularly to address thymus damage caused by chemoradiotherapy in hematopoietic stem cell transplantation.

Method used

A method involving the culture of CD34+ cells in the presence of aromatic hydrocarbon receptor antagonists like StemRegenin-1 (SR1) and LSD1 degradation inducers such as UM171, along with additional factors like fibronectin, Delta-like 4 (DLL4), stem cell factor (SCF), interleukin-3 (IL-3), and interleukin-6 (IL-6), to efficiently differentiate cells into T progenitor cells.

Benefits of technology

This method enables the high-efficiency production of T progenitor cells, as demonstrated by flow cytometry results, which can effectively promote T cell recovery and have potential applications in cancer treatment by differentiating into T cells and targeting cancer cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JP2024020073_05122024_PF_FP_ABST
    Figure JP2024020073_05122024_PF_FP_ABST
Patent Text Reader

Abstract

Disclosed are: a method for producing a cell population comprising T precursor cells, the method comprising step (1) for culturing a cell population containing CD34+ cells in the presence of an aromatic hydrocarbon receptor antagonist and an LSD1 degradation inducing agent; a cell population comprising T precursor cells obtained by this method; a medicament containing the cell population comprising T precursor cells; and a T cell progenitor inducing agent comprising an aromatic hydrocarbon receptor antagonist and an LSD1 degradation inducer.
Need to check novelty before this filing date? Find Prior Art

Description

Method for producing T cell precursors

[0001] The present invention relates to a method for producing a cell population containing T precursor cells, a cell population containing T precursor cells obtained by the method, a pharmaceutical comprising the cell population containing T precursor cells, a T precursor cell inducer, and the like. (Background of the Invention)

[0002] Hematopoietic stem cell transplantation (HSCT) is the current standard treatment for many malignant and non-malignant hematopoietic diseases. Before the donor graft, hematopoietic stem cells (HSCs), are infused (transplanted), patients must undergo a conditioning regimen including chemotherapy or chemoradiotherapy. This conditioning severely damages the thymic microenvironment, resulting in peripheral CD4 + and CD8 + It delays T-cell reconstitution and makes the patient vulnerable to opportunistic infections. The component of the thymic microenvironment most susceptible to damage by chemoradiotherapy is the thymic epithelial cell, and such damage contributes to the long-term impairment of thymus formation after transplantation.

[0003] While the above-mentioned pretreatment causes problems in thymocyte development, infusion therapy with in vitro-derived T cell progenitors (proT) via hematopoietic stem cell transplantation is known to promote recovery of the thymus damaged by radiation. Therefore, in recent years, research and development of cell therapy using T cell progenitors (proT therapy) has been progressing for the purpose of recovering T cells due to thymic damage after radiation therapy.

[0004] Non-Patent Document 1 describes that the co-addition of SR1 and UM171 can stimulate the proliferation of hematopoietic stem cells derived from human umbilical cord blood in vitro.

[0005] In Patent Document 1, CD34 + UM171 has been described as a compound that promotes cell expansion.

[0006] However, considering the future practical application of proT therapy, an industrial method for producing proT with high production efficiency (yield) is desired, but no report on such a production method has been found to date.

[0007] International Publication No. 2019 / 067811

[0008] Fares et al., Science, 345 (6203), 1509-1512, 2014

[0009] An object of the present invention is to provide a method for producing T precursor cells, a T precursor cell inducer, and the like, which can produce a cell population containing T precursor cells with high efficiency.

[0010] As a result of extensive research to achieve the above object, the present inventors have discovered that CD34 + Cells (especially CD34 + / CD43 - / CD184 - / CD73 - It has been found that LSD1 cells can be differentiated into T cell precursors with high efficiency by culturing them in the presence of an aryl hydrocarbon receptor antagonist (e.g., SR1) and an LSD1 degradation inducer (e.g., UM171).

[0011] The present invention was completed based on these findings and through further investigation, and provides the following method for producing T precursor cells, T precursor cells, pharmaceuticals, T precursor cell inducers, etc.

[0012] [1] A method for producing a cell population containing T cell precursors, comprising the steps of: (1) activating CD34 T cells in the presence of an aromatic hydrocarbon receptor antagonist and an LSD1 degradation inducer; + [2] The method according to [1], wherein the aromatic hydrocarbon receptor antagonist is StemRegenin-1 (SR1). [3] The method according to [1] or [2], wherein the LSD1 degradation inducer is UM171. [4] The method according to [1], wherein the step (1) further comprises culturing a cell population containing CD34 cells in the presence of fibronectin or a fragment thereof, and / or Delta-like 4 (DLL4). + [5] The method according to any one of [1] to [3], wherein the step (1) is a step of culturing cells in the presence of at least one selected from the group consisting of stem cell factor (SCF), interleukin-3 (IL-3), and interleukin-6 (IL-6).+ [5a] The method according to any one of [1] to [5], wherein the medium used in the step (1) contains IMDM, L-alanyl-L-glutamine (and / or GlutaMAX (trade name)), and albumin. [6] The method according to any one of [1] to [5], wherein the medium used in the step (1) contains CD34 + The cells are CD34 + / CD43 - / CD184 - / CD73 - [7] The method according to any one of [1] to [5a], wherein the CD34 + [8a] (A) The method according to any one of [1] to [6], wherein the cell population containing the T cells is derived from induced pluripotent stem cells (iPS cells). [8] The method according to any one of [1] to [7], wherein the T cell precursors contain a foreign gene encoding a receptor (particularly a chimeric antigen receptor). [8a] (A) The method according to any one of [1] to [7], further comprising a step of preparing iPS cells, wherein in step (1), CD34 derived from the iPS cells is expressed. + [8b] (B) The method according to any one of [1] to [8], wherein a cell population containing iPS cells is used. + The method further comprises a step of inducing differentiation into a cell population containing CD34 cells, + [8c] (C) The method according to any one of [1] to [8a], wherein a cell population containing CD34 cells is used. + Hematopoietic vascular endothelial cells (CD34 + / CD43 - / CD184 - / CD73 -The method of [8b] further comprises a step of selecting a cell population containing T cell precursors (T cell precursors). [9] A cell population containing T cell precursors obtained by the method of any of [1] to [8c].

[10] A pharmaceutical comprising the cell population containing T cell precursors according to [9].

[11] The pharmaceutical of

[10] , which is a preventive and / or therapeutic agent for cancer.

[12] A T cell precursor inducer comprising an aryl hydrocarbon receptor antagonist and an LSD1 degradation inducer.

[13] The agent of

[12] , wherein the aryl hydrocarbon receptor antagonist is SR1.

[14] The agent of

[12] or

[13] , wherein the LSD1 degradation inducer is UM171.

[15] The agent of any of

[12] to

[14] , further comprising fibronectin or a fragment thereof, and / or DLL4.

[16] The agent of

[15] , further comprising at least one member selected from the group consisting of SCF, IL-3, and IL-6.

[17] A method for preventing and / or treating cancer, comprising administering a cell population comprising T cell precursors according to [9] to a subject in need thereof.

[18] A cell population comprising T cell precursors according to [9] for use in the prevention and / or treatment of cancer.

[19] Use of a cell population comprising T cell precursors according to [9] in the manufacture of a medicament for preventing and / or treating cancer.

[20] A culture medium for differentiating T cell precursors, comprising an aryl hydrocarbon receptor antagonist and an LSD1 degradation inducer.

[21] The culture medium according to

[20] , wherein the aryl hydrocarbon receptor antagonist is SR1.

[22] The culture medium according to

[20] or

[21] , wherein the LSD1 degradation inducer is UM171.

[23] The culture medium according to any of

[20] to

[22] , further comprising fibronectin or a fragment thereof, and / or DLL4.

[24] The culture medium according to any of

[20] to

[23] , further comprising at least one selected from the group consisting of SCF, IL-3, and IL-6.

[25] A kit for differentiating T cell precursors, comprising an aryl hydrocarbon receptor antagonist and an LSD1 degradation inducer.

[26] The kit according to

[25] , wherein the aryl hydrocarbon receptor antagonist is SR1.

[27] The kit according to

[25] or

[26] , wherein the LSD1 degradation inducer is UM171.

[28] The kit according to any one of

[25] to

[27] , further comprising fibronectin or a fragment thereof, and / or DLL4.

[29] The kit according to any one of

[25] to

[28] , further comprising at least one selected from the group consisting of SCF, IL-3, and IL-6.

[0013] According to the present invention, CD34 can be efficiently isolated. + It is possible to produce a cell population containing T cell precursors from a cell population containing T cells.

[0014]

[0033] Figure 1 shows the results of flow cytometry performed on antibody staining of a cell population containing HECs obtained by differentiation from induced pluripotent stem cells. Figure 2 shows the results of flow cytometry performed on antibody staining of a cell population containing T progenitor cells obtained by differentiation from induced pluripotent stem cells. Figure 3 shows the results of flow cytometry performed on antibody staining of a cell population containing T progenitor cells obtained by differentiation from induced pluripotent stem cells. Figure 4 shows the results of flow cytometry performed on antibody staining of a cell population containing T progenitor cells obtained by differentiation from induced pluripotent stem cells. Figure 5 shows a graph of the proportion of T progenitor cells in a cell population containing T progenitor cells obtained by differentiation from induced pluripotent stem cells. In the graph, U represents UM171, and S represents SR1. Values ​​in the graph represent mean ± SEM, n = 3. Figure 1 shows the results of flow cytometry performed on antibody staining of blood cells collected 8 weeks after transplantation of a cell population containing T progenitor cells obtained by differentiation from induced pluripotent stem cells into mice. Figure 2 shows the results of flow cytometry performed on antibody staining of blood cells collected 12 weeks after transplantation of a cell population containing T progenitor cells obtained by differentiation from induced pluripotent stem cells into mice.

[0033] Figure 1 shows the results of flow cytometry performed with an antibody on thymic cells collected 4 weeks after transplantation of a cell population containing T precursor cells obtained by differentiation from induced pluripotent stem cells into mice.

[0034] Figure 1 shows the results of production of CAR-expressing T precursor cells. Top: outline of the method for producing CAR-expressing T precursor cells. Middle: flow cytometry results on antibody staining of a cell population containing gene-transfected T precursor cells. Bottom: graphs showing the copy numbers of lentivirus and CAR per cell.

[0035] Figure 1 shows the results of administering a B cell tumor line to mice transplanted with CAR-expressing T precursor cells. Top: outline of an experiment for evaluating the in vivo anticancer activity of CAR-expressing T precursor cells. Bottom: flow cytometry results on antibody staining of blood cells collected 8 to 12 weeks after transplantation of a cell population containing CAR-expressing T precursor cells into mice.

[0036] Figure 1 shows the results of administering a B cell tumor line to mice transplanted with CAR-expressing T precursor cells. Upper panel: Outline of an experiment to evaluate the in vivo anti-cancer activity of CAR-expressing T precursor cells. Lower panel: Images of luciferase luminescence from the B cell tumor line NALM-6 9 to 12 weeks after transplantation of a cell population containing CAR-expressing T precursor cells into mice.

[0015] Hereinafter, embodiments of the present invention will be described in detail.

[0016] "Comprise(s)" or "comprising" means the inclusion of, but is not limited to, the elements that follow the phrase. Thus, it implies the inclusion of the elements that follow the phrase, but not the exclusion of any other elements. "Consist(s) of" or "consisting of" means inclusive of and limited to any elements that follow the phrase. Thus, the phrase "consisting of" indicates that the listed elements are required or essential, with other elements being substantially absent. "Consist(s) essentially of" or "consisting essentially of" means inclusive of any elements that follow the phrase, and is limited to other elements that do not affect the activity or function of the element identified in this disclosure. Thus, the phrase "consisting essentially of" indicates that the recited elements are required or essential, but that other elements are optional and may or may not be present depending on whether they affect the activity or function of the recited elements.

[0017] As used herein, "culturing" refers to maintaining and / or growing cells in an in vitro environment. "Culturing" refers to maintaining and / or growing cells outside a tissue or body, for example, in a cell culture dish or flask.

[0018] As used herein, "culturing cells in the presence of a substance" refers to, for example, culturing cells in a medium containing the substance. Examples of such culturing include culturing in a medium containing the substance alone, or in a medium containing the substance together with other differentiation-inducing factors. When the substance is added to the medium, it can be added directly to the medium, or the substance can be dissolved in an appropriate solvent just before use and then added to the medium. The substance can also be immobilized on the surface of a substrate or carrier during culturing and then cultured.

[0019] As used herein, "positive (+)" means that the protein or gene is expressed in an amount that can be detected by a method known in the art. In addition, in the case of a protein that is expressed intracellularly and not present on the cell surface (e.g., a transcription factor or a subunit thereof), the protein of interest can be detected by expressing a reporter protein together with the protein and detecting the reporter protein. Gene detection can be carried out using, for example, nucleic acid amplification methods and / or nucleic acid detection methods such as RT-PCR, microarrays, biochips, and RNAseq.

[0020] As used herein, "negative (-)" means that the expression level of a protein or gene is below the lower limit of detection by all or any of the above-mentioned known techniques, or that the level of expression is low. The lower limit of detection for protein or gene expression may vary depending on the technique. The level of protein or gene expression (whether low or high expression) can be determined by comparing it with the results of control cells measured under the same conditions. For example, the level of CD7 expression in a certain cell population can be determined using flow cytometry, by comparing the CD7 expression level in the cell population with the control; if expression is equivalent to that of the control, it is determined to be low expression, and if expression is higher than that of the control cells, it is determined to be high expression.

[0021] As used herein, the term "marker" refers to a protein or its gene that is specifically expressed on the cell surface, in the cytoplasm, in the nucleus, etc., in a specific cell type. The marker is preferably a "cell surface marker." A "cell surface marker" refers to a protein expressed on the cell surface that can be labeled (stained) with a fluorescent substance, and that facilitates the detection, concentration, isolation, etc., of cells expressing the cell surface marker. The cell surface marker refers to a gene that is specifically expressed (positive marker) or not expressed (negative marker) in a specific cell type, specifically a substance that is produced (positive marker) or not produced (negative marker) as mRNA by transcription of the gene in the genome, or as a protein by translation of that mRNA.

[0022] Such cell surface markers can be detected by immunological assays using antibodies specific to the cell surface markers, such as ELISA, immunostaining, and flow cytometry.

[0023] As used herein, "expression" is defined as the transcription and / or translation of a particular nucleotide sequence driven by a promoter within a cell.

[0024] As used herein, the term "pluripotent stem cells" refers to embryonic stem cells (ES cells) and cells that have the same pluripotency, i.e., the potential to differentiate into various tissues in the body (all of the endoderm, mesoderm, and ectoderm). Cells that have the same pluripotency as ES cells include "induced pluripotent stem cells" (sometimes referred to as "iPS cells" in this specification).

[0025] As used herein, "hematopoietic stem cells" refer to multipotent stem cells that can differentiate into blood cells and are CD45- and CD34-positive. In the human body, hematopoietic stem cells are primarily present in the bone marrow and differentiate into leukocytes (neutrophils, eosinophils, basophils, lymphocytes, monocytes, macrophages), erythrocytes, platelets, mast cells, dendritic cells, and the like. In the present invention, hematopoietic stem cells may be cells isolated from biological tissues such as bone marrow, or may be cells derived from ES cells and iPS cells.

[0026] As used herein, "hematopoietic progenitor cells" refer to cells that can differentiate into blood cells such as lymphocytes, eosinophils, neutrophils, basophils, erythrocytes, and megakaryocytes, and hematopoietic progenitor cells can be recognized by being positive for the surface antigens CD34 and / or CD43.

[0027] As used herein, the term "T cell precursor" (sometimes referred to as proT cell or proT cell) refers to hematopoietic cells that arise in the human body during the process of differentiation from hematopoietic stem cells (HSC) to CD3-positive T cells, and are CD34 and CD7 positive (CD34+ / CD7 + cells), and may also be CD144 positive (CD34 + / CD7 + / CD144 + Also, as used herein, proT may be negative for CD43, CD1a, and / or CD116.

[0028] As used herein, the term "cell population" refers to two or more cells of the same or different types. The term "cell population" also refers to a mass of cells of the same or different types.

[0029] CD34 used in the present invention + The cells are not particularly limited, and may be, for example, CD34 cells induced in vitro according to known techniques. + The cells may be CD34-positive hematopoietic endothelial cells (HECs) induced from pluripotent stem cells, or CD34-positive hematopoietic endothelial cells isolated from living tissue by known methods. + It may also be a cell.

[0030] Pluripotent stem cells are subjected to a method known per se to induce the expression of CD34 + When the pluripotent stem cells are iPS cells, hematopoietic progenitor cells can be differentiated and differentiated to CD34 by the methods described in, for example, WO 2017 / 221975, WO 2018 / 135646, and Cell Reports 2 (2012) 1722-1735. + The cells can be manufactured.

[0031] In addition, the above CD34 + The biological tissue from which the cells are isolated includes CD34 + There is no limitation as long as it contains cells, but examples include bone marrow, umbilical cord blood, blood, thymus, and the like.

[0032] From the viewpoint of therapeutic application, the various cells used in the present invention are preferably cells that comply with GMP (Good Manufacturing Practice) standards.

[0033] Examples of the pluripotent stem cells include embryonic stem cells (ES cells), induced pluripotent stem cells (iPS cells), embryonic tumor cells (EC cells), and embryonic germ stem cells (EG cells), and preferably iPS cells (more preferably human iPS cells). When the pluripotent stem cells are ES cells or any cells derived from a human embryo, the cells may be cells produced by destroying an embryo or cells produced without destroying an embryo, and preferably cells produced without destroying an embryo.

[0034] As for "ES cells," in the case of mouse ES cells, various mouse ES cell lines established by inGenious targeting laboratory, RIKEN (Institute of Physical and Chemical Research), etc. can be used, and in the case of human ES cells, various human ES cell lines established by University of Wisconsin, NIH, RIKEN, Kyoto University, National Center for Child Health and Development, Cellartis, etc. can be used. For example, human ES cell lines that can be used include CHB-1 to CHB-12 strains, RUES1 strain, RUES2 strain, HUES1 to HUES28 strains, etc. distributed by ESI Bio, H1 strain, H9 strain, etc. distributed by WiCell Research, and KhES-1 strain, KhES-2 strain, KhES-3 strain, KhES-4 strain, KhES-5 strain, SSES1 strain, SSES2 strain, SSES3 strain, etc. distributed by RIKEN.

[0035] "Induced pluripotent stem cells" refer to cells obtained by reprogramming mammalian somatic cells or undifferentiated stem cells by introducing specific factors (nuclear reprogramming factors). Currently, there are various types of "induced pluripotent stem cells," including iPS cells established by Yamanaka et al. by introducing four factors, Oct3 / 4, Sox2, Klf4, and c-Myc, into mouse fibroblasts (Takahashi K, Yamanaka S., Cell, (2006) 126: 663-676), human-derived iPS cells established by introducing the same four factors into human fibroblasts (Takahashi K, Yamanaka S., et al. Cell, (2007) 131: 861-872), and Nanog-iPS cells established by selecting using Nanog expression as an indicator after introducing the above four factors (Okita, K., Ichisaka, T., and Yamanaka, S. (2007). Nature 448, 313-317.), iPS cells produced by a method that does not contain c-Myc (Nakagawa M, Yamanaka S., et al. Nature Biotechnology, (2008) 26, 101-106), and iPS cells established by introducing six factors using a virus-free method (Okita K et al. Nat. Methods 2011 May; 8(5): 409-12, Okita K et al. Stem Cells. 31(3): 458-66.) can also be used. In addition, induced pluripotent stem cells established by introducing four factors, OCT3 / 4, SOX2, NANOG, and LIN28, produced by Thomson et al. (Yu J., Thomson JA. et al., Science (2007) 318: 1917-1920.), induced pluripotent stem cells produced by Daley et al. (Park IH, Daley GQ. et al., Nature (2007) 451: 141-146), induced pluripotent stem cells produced by Sakurada et al. (Japanese Patent Laid-Open Publication No. 2008-307007), and the like can also be used.

[0036] In addition, all published papers (e.g., Shi Y., Ding S., et al., Cell Stem Cell, (2008) Vol. 3, Issue 5, 568-574; Kim JB., Scholeer HR., et al., Nature, (2008) 454, 646-650; Huangfu D., Melton DA., et al., Nature Biotechnology, (2008) 26, No. 7,795-797), or patents (e.g., JP 2008-307007 A, JP 2008-283972 A, U.S. Patent Application Publication No. 2008 / 2336610, U.S. Patent Application Publication No. 2009 / 047263, WO 2007 / 069666, WO 2008 / 118220, WO 2008 / 124133, WO 2008 / 151058, WO 2009 / 006930, WO 2009 / 006997, WO 2009 / 007852) Any of the induced pluripotent stem cells known in the art can be used.

[0037] As induced pluripotent stem cell lines, various iPS cell lines established by the NIH, RIKEN, Kyoto University, etc. can be used. Examples of human iPS cell lines include RIKEN's HiPS-RIKEN-1A strain, HiPS-RIKEN-2A strain, HiPS-RIKEN-12A strain, and Nips-B2 strain, and Kyoto University's Ff-I01s04 strain, Ff-WJc513 strain, QHJI strain, RWMH strain, DRXT strain, RJWI strain, YZWJ strain, ILCL strain, GLKV strain, 253G1 strain, 201B7 strain, 409B2 strain, 454E2 strain, 606A1 strain, 610B1 strain, and 648A1 strain.

[0038] The term "nucleic acid" refers to any molecule formed by polymerizing nucleotides and molecules having functions equivalent to those nucleotides, such as RNA, which is a polymer of ribonucleotides; DNA, which is a polymer of deoxyribonucleotides; a mixed polymer of ribonucleotides and deoxyribonucleotides; and a nucleotide polymer containing a nucleotide analogue. Nucleic acids may also be single-stranded or double-stranded nucleic acids. Double-stranded nucleic acids also include double-stranded nucleic acids in which one strand hybridizes to the other strand under stringent conditions.

[0039] The nucleotide analogue may be any molecule obtained by modifying ribonucleotides, deoxyribonucleotides, RNA, or DNA to improve or stabilize nuclease resistance, increase affinity with a complementary nucleic acid strand, increase cell permeability, or enable visualization, compared to RNA or DNA. The nucleotide analogue may be a naturally occurring molecule or a non-natural molecule, and examples thereof include sugar-modified nucleotide analogues (e.g., nucleotide analogues substituted with 2'-O-methylribose, nucleotide analogues substituted with 2'-O-propylribose, nucleotide analogues substituted with 2'-methoxyethoxyribose, nucleotide analogues substituted with 2'-O-methoxyethylribose, nucleotide analogues substituted with 2'-O-[2-(guanidium)ethyl]ribose, nucleotide analogues substituted with 2'-fluororibose, bridged artificial nucleic acid (BNA), locked artificial nucleic acid (LNA), ethylene bridged artificial nucleic acid (ENA), and the like. acid), peptide nucleic acid (PNA), oxypeptide nucleic acid (OPNA), peptide ribonucleic acid (PRNA)), nucleotide analogs modified with a phosphodiester bond (e.g., nucleotide analogs substituted with a phosphorothioate bond, nucleotide analogs substituted with an N3'-P5' phosphoamidate bond), etc.

[0040] The nucleic acid derivative may be any molecule in which another chemical substance is added to the nucleic acid in order to improve nuclease resistance, stabilization, affinity with a complementary nucleic acid strand, cell permeability, or visualization, compared to nucleic acids. Specific examples include 5'-polyamine-added derivatives, cholesterol-added derivatives, steroid-added derivatives, bile acid-added derivatives, vitamin-added derivatives, Cy5-added derivatives, Cy3-added derivatives, 6-FAM-added derivatives, and biotin-added derivatives.

[0041] The method for producing a cell population containing T cell precursors of the present invention (hereinafter, sometimes simply referred to as the "production method of the present invention") is characterized by comprising the following steps: (1) selectively activating CD34 in the presence of an aromatic hydrocarbon receptor antagonist and an LSD1 degradation inducer; + Culturing a cell population containing the cells

[0042] CD34 + As a medium for culturing a cell population containing cells, a medium used for culturing animal cells can be used as a basal medium. The basal medium is not particularly limited as long as it can be used for culturing animal cells, and examples thereof include Iscove's Modified Doulbecco's Medium (IMDM) medium, Medium 199 medium, Eagle's Minimum Essential Medium (EMEM) medium, αMEM medium, Doulbecco's modified Eagle's Medium (DMEM) medium, Ham's F12 medium, RPMI 1640 medium, Fischer's medium, MCDB 131 medium, Neurobasal Medium (Life Technologies), StemSpan SFEM II (StemCell technologies), a mixed medium thereof, etc. + Media for culturing cell populations containing cells include media containing IMDM, L-alanyl-L-glutamine (eg, GlutaMAX™), and albumin (eg, human albumin), among others.

[0043] The aryl hydrocarbon receptor (AHR) is a transcription factor belonging to the Per / ARNT / SIM (PAS) family. AHR is inactive when no ligand is bound, but upon binding of an aromatic hydrocarbon compound as a ligand, it translocates into the nucleus, where it forms a heterodimer with a molecule called ARNT (AhR Nuclear Translocator), which binds to the xenobiotic response element (XRE) on DNA, thereby activating transcription. An aromatic hydrocarbon receptor antagonist (AHR antagonist) is a substance that inhibits at least part or all of the response that occurs when an agonist binds to AHR. AHR antagonists may act directly on AHR, or may act indirectly on AHR via an effect on another substance.

[0044] The aromatic hydrocarbon receptor antagonist is not particularly limited, and examples thereof include low molecular weight compounds, high molecular weight compounds, proteins such as antibodies and fragments thereof, peptides, and nucleic acids. Specific examples include SR1 (4-(2-((2-(benzo[b]thiophen-3-yl)-9-isopropyl-9H-purin-6-yl)amino)ethyl)phenol), α-naphthoflavone, 1,4-dihydroxyanthraquinone, 1,5-dihydroxyanthraquinone, 1,8-dihydroxyanthraquinone, galangin, resveratrol, PD98059, CH-223191, GNF-351, TSU-16, 6,2',4'-trimethoxyflavone, 3',4'-dimethoxyflavone, and compounds described as AHR antagonists in WO 2012 / 015914. Of these, SR1 is preferred.

[0045] The concentration of the AHR antagonist in the medium is not particularly limited as long as it allows the production of T cell precursors, and is appropriately adjusted depending on the type of AHR antagonist used. For example, when the AHR antagonist is SR1, the concentration can be 0.1 nM to 3000 nM, preferably 10 nM to 2000 nM, and more preferably 100 nM to 1500 nM.

[0046] LSD1 (lysine-specific demethylase 1) is an enzyme that demethylates monomethylated or dimethylated lysine residues in histones, and is also a constituent protein of various corepressor complexes. This property gives it the function of epigenetically regulating genes. An LSD1 degradation inducer refers to a substance that induces the degradation of LSD1. An LSD1 degradation inducer can also be called a CoREST degradation inducer. An LSD1 degradation inducer may act directly on LSD1, or may indirectly induce the degradation of LSD1 through its action on another substance.

[0047] The LSD1 degradation inducer is not particularly limited, and examples thereof include low molecular weight compounds, high molecular weight compounds, proteins such as antibodies and fragments thereof, peptides, and nucleic acids. Specific examples include UM171 (4-N-[2-benzyl-7-(2-methyltetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl]cyclohexane-1,4-diamine), UM729 (methyl 4-((3-(piperidin-1-yl)propyl)amino)-9H-pyrimido[4,5-b]indole-7-carboxylate), and the like. Of these, UM171 is preferred.

[0048] The concentration of the LSD1 degradation inducer in the medium is not particularly limited as long as it allows the production of T cell precursors, and is appropriately adjusted depending on the type of LSD1 degradation inducer used. For example, when the LSD1 degradation inducer is UM171, the concentration can be 1.0 nM to 300 nM, preferably 3.0 nM to 100 nM.

[0049] In step (1), CD34 is further isolated in the presence of fibronectin or a fragment thereof, and / or DLL4. + In step (1), a cell population containing CD34 cells can be cultured in the presence of two or more of (i) fibronectin or a fragment thereof, and (ii) DLL4. + Preferably, the cell population comprising the cells is cultured.

[0050] The above-mentioned fibronectin (FN) fragment can be selected from fragments contained in the FN-binding domain, cell adhesion domain, or heparin-binding domain. 1 , III 2 , III 3 , III 7 , III 8 , III 9 , III 11 , III 12 , III 13 and CS-1, and may further include a fragment in which multiple domains are repeatedly linked. Examples of fibronectin fragments include a cell adhesion domain containing a ligand for VLA-5, a heparin-binding domain, a CS-1 domain which is a ligand for VLA-4, a III domain, a CS-2 domain which is a ligand for VLA-5, a VLA-3 domain, a VLA-4 domain, a VLA-5 domain, a VLA-5 domain, a VLA-6 domain, a VLA-7 domain, a VLA-8 domain, a VLA-9 domain, a VLA-10 domain, a VLA-11 domain, a VLA-12 domain, a VLA-13 domain, a VLA-14 domain, a VLA-15 domain, a VLA-16 domain, a VLA-17 domain, a VLA-18 domain, a VLA-19 domain, a VLA-19 domain, a VLA-20 domain, a VLA-21 domain, a VLA-22 domain, a VLA-23 domain, a VLA-24 domain, a VLA-25 domain, a VLA-26 domain, a VLA-27 domain, a VLA-28 domain, a VLA-29 domain, a VLA-30 domain, a VLA-31 domain, a VLA-32 domain, a VLA-33 domain, a VLA-34 domain, a VLA-35 domain, a VLA-36 domain, a VLA-37 domain, a VLA-38 domain, a VLA-39 domain, a VLA-41 domain, a VLA-42 domain, a VLA-43 domain, a VLA-44 domain, a VLA-45 domain, a VLA-45 domain, a VLA-46 domain, a VLA-47 domain, a VLA-48 domain, a VLA-49 domain, a VLA-49 domain, a VLA-49 domain, a VLA-49 domain, a VLA-49 domain, a VLA-41 domain 1 Fragments containing the above can be used. Further, examples of fibronectin fragments include CH-271, CH-296, H-271, H-296, and derivatives and modifications thereof, which are described in J. Biochem., Vol. 110, pp. 284-291 (1991). CH-296 is commercially available under the name RetroNectin (trademark). Also, III 1 The C-terminal two-thirds of the polypeptide is Fibronectin Fragment III. 1 It is commercially available under the name -C.

[0051] FN and its fragments may be immobilized on an appropriate solid phase, such as a cell culture carrier, such as a cell cultureware, beads, membrane, or glass slide. Immobilization of FN and / or its fragments on a solid phase can be performed, for example, according to the method described in International Publication No. 00 / 09168. The concentration of FN and / or its fragments in the medium is not particularly limited as long as it allows the production of T cell precursors. For example, a concentration of 0.001 μg / mL to 500 μg / mL is preferred, and 0.01 μg / mL to 500 μg / mL is more preferred. When using immobilized FN and its fragments, immobilization on a solid phase can be performed using a solution of FN and its fragments at the above-mentioned concentrations. Culturing a cell population in the presence of FN and its fragments is described in International Publication No. 03 / 080817, and can be performed with reference to this document. DLL4 can also be immobilized on a cell culture carrier using a similar method. When FN or a fragment thereof, and DLL4 are used after immobilization on a solid phase, they do not need to be contained in the culture medium for differentiation of T cell precursors. The concentration of DLL4 in the culture medium is not particularly limited as long as it allows the production of T cell precursors, and is, for example, preferably 0.001 μg / mL to 500 μg / mL, and more preferably 0.01 μg / mL to 500 μg / mL.

[0052] In step (1), CD34 is isolated in the presence of stem cell factor (SCF), IL-3, and IL-6. + In step (1), two or more of (iii) SCF, (iv) IL-3, and (v) IL-6 are preferably contained, and three of them are more preferably contained.

[0053] The concentration of SCF in the medium can be, for example, 3 ng / mL to 3000 ng / mL, preferably 10 ng / mL to 1000 ng / mL, and more preferably 30 ng / mL to 300 ng / mL.

[0054] The concentration of IL-3 in the medium can be, for example, 0.5 ng / mL to 1000 ng / mL, preferably 1 ng / mL to 500 ng / mL, and more preferably 1 ng / mL to 300 ng / mL.

[0055] The concentration of IL-6 in the medium can be, for example, 0.5 ng / mL to 1000 ng / mL, preferably 1 ng / mL to 500 ng / mL, and more preferably 1 ng / mL to 300 ng / mL.

[0056] In step (1), CD34 is induced in the presence of, in addition to the above-mentioned components, for example, thrombopoietin (TPO), Flt3L (Fms-like tyrosine kinase 3 ligand), IL-7, etc. + The cell population comprising the cells may be cultured.

[0057] Furthermore, aromatic hydrocarbon receptor antagonists, LSD1 degradation inducers, etc. can be used in their free state or in the form of a salt. Examples of salts include salts with inorganic bases such as sodium salts, magnesium salts, potassium salts, calcium salts, and aluminum salts; salts with organic bases such as methylamine salts, ethylamine salts, and ethanolamine salts; salts with basic amino acids such as lysine, ornithine, and arginine, and ammonium salts. The salts may be acid addition salts, and specific examples of such salts include acid addition salts with mineral acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, and phosphoric acid; organic acids such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, malic acid, tartaric acid, fumaric acid, succinic acid, lactic acid, maleic acid, citric acid, methanesulfonic acid, and ethanesulfonic acid; and acidic amino acids such as aspartic acid and glutamic acid. The aromatic hydrocarbon receptor antagonists, LSD1 decomposition inducers, etc. also include hydrates, solvates, crystalline polymorphs, etc.

[0058] CD34 + The medium for culturing the cell population containing the cells may contain serum or may be serum-free, and is preferably serum-free.

[0059] CD34 +The medium for culturing the cell population containing the cells may also contain a serum substitute (e.g., albumin, transferrin, Knockout Serum Replacement (KSR), fatty acids, insulin, collagen precursors, trace elements, 2-mercaptoethanol, 3'-thiolglycerol, ITS supplement, etc.). One or more types of serum substitutes can be used.

[0060] Furthermore, CD34 + The medium in which the cell population containing the cells is cultured can also contain one or more substances such as lipids, amino acids (such as non-essential amino acids), L-glutamine, vitamins, growth factors, cytokines, antibiotics, antioxidants, pyruvate, buffers, inorganic salts, and the like.

[0061] CD34 + As a medium for culturing a cell population containing T cells, it is desirable to use a chemically defined medium that does not contain unknown components such as serum, because this reduces the difference between medium lots and allows the preparation of a cell population containing T precursor cells of stable quality.

[0062] CD34 + The pH of the medium for culturing the cell population containing the cells is usually 7.0 to 7.8, preferably 7.2 to 7.6. The medium is preferably sterilized by filtration, ultraviolet irradiation, heat sterilization, radiation exposure, or the like to prevent contamination before use.

[0063] CD34 + The medium for culturing a cell population containing cells can be prepared in the form of a solution, a dry form, or a concentrated form (e.g., 2x to 1000x). In the case of a concentrated form, it can be used after being diluted appropriately to an appropriate concentration. The liquid used to dilute the dry or concentrated form of the medium can be appropriately selected from water, an aqueous buffer solution, a physiological saline solution, etc.

[0064] The culture in the present invention may be either an adherent culture or a suspension culture.

[0065] The production method of the present invention is preferably carried out in the absence of feeder cells. Because the production method of the present invention allows culture in the absence of feeder cells, it is possible to stably produce a cell population containing T cell precursors with uniform properties without contamination with unknown components.

[0066] As used herein, "in the absence of feeder cells" or "feeder-free" means that feeder cells are not essentially contained, and that a medium preconditioned by culturing feeder cells is not used. Therefore, the medium does not contain substances such as growth factors and cytokines secreted by feeder cells.

[0067] The term "feeder cells" or "feeders" refers to cells that are co-cultured with other types of cells and provide an environment in which the cells can grow and support them. Feeder cells may be derived from the same or a different species as the cells they support. For example, human dermal fibroblasts or human embryonic stem cells may be used as feeders for human cells, as well as primary cultures of mouse embryonic fibroblasts and immortalized mouse embryonic fibroblasts. Feeder cells can be inactivated by irradiation or mitomycin C treatment, for example.

[0068] The culture conditions for the production method of the present invention are not particularly limited, and the culture temperature is, for example, about 37 to 42°C, preferably about 37 to 39°C. The culture period is also not particularly limited, and can be appropriately determined by a person skilled in the art while monitoring the number of T cell precursors, and is, for example, 10 days or more. In the culture of the present invention, passages may be performed as many times as necessary to obtain a cell population containing a desired amount of T cell precursors, and the medium may be added and replaced. The culture of the present invention can be performed using known CO 2 This can be done using an incubator.

[0069] CD34 used in the production method of the present invention + The cells were CD34 positive (CD34 + In one embodiment, the cells are CD34 positive and CD7 negative (CD34+ / CD7 - In another embodiment, the cells are CD34 + The cells are hemogenic endothelial cells (HECs). The HECs are CD34 positive and CD45 and CD43 negative. The HECs may also be CD184 and CD73 negative. The HECs may be CD34 positive and CD45 and CD43 negative. + / CD43 - / CD45 - / CD184 - / CD73 - It can be a CD34 cell (including + / CD43 - / CD45 - / CD184 - / CD73 - The cells do not express CD7, so CD34 + / CD43 - / CD45 - / CD184 - / CD73 - The cells are CD34 + / CD7 - / CD43 - / CD45 - / CD184 - / CD73 - HECs may also be negative for CD14 and CD235a. - / CD235a - / CD34 + / CD43 - / CD184 - / CD73 - Thus, by using HECs in step (1), it becomes possible to produce precursor T cells with higher efficiency.

[0070] The production method of the present invention may further comprise the step (A) of preparing iPS cells.

[0071] The method for preparing iPS cells includes the method described above. + and inducing differentiation into a cell population containing the CD34 +A cell population containing iPS cells can be used for the culture in step (1). In the present invention, when pluripotent stem cells other than iPS cells are used, the other pluripotent stem cells are prepared in place of iPS cells in step (A).

[0072] Pluripotent stem cells, cells for producing pluripotent stem cells, and CD34 used in the present invention + The cell population containing the cells may be derived from humans or non-human mammals, preferably humans. Examples of non-human mammals include mice, rats, hamsters, guinea pigs, rabbits, dogs, cats, pigs, cows, horses, sheep, and monkeys. Universalized iPS cells (i.e., cells with a specific HLA type or knockout HLA that do not cause immune rejection in many patients) can also be used.

[0073] The production method of the present invention further comprises: (B) transfecting pluripotent stem cells with CD34 + The method may further comprise the step of inducing differentiation into a cell population containing the cells.

[0074] Here, differentiation-induced CD34 + The cell population containing the cells can be used for the culture in step (1). + The differentiation of hematopoietic progenitor cells into a cell population containing pluripotent stem cells can be carried out according to known methods. When the pluripotent stem cells are iPS cells, for example, hematopoietic progenitor cells can be induced to differentiate into CD34 cells by the methods described in WO 2017 / 221975, WO 2018 / 135646, and Cell Reports 2 (2012) 1722-1735. + A cell population comprising the cells can be produced.

[0075] CD34 used in the production method of the present invention + The cell population containing T cells is a CD34 T cell-expressing cell that has been induced to differentiate from pluripotent stem cells (particularly iPS cells (especially human iPS cells)). + It may be a cell population containing T cells. + CD34 in cell populations including T cells +The proportion (cell number) of T cells is, for example, 5% or more, preferably 50% or more, more preferably 90% or more, and the upper limit is, for example, 100% or less.

[0076] The production method of the present invention comprises: (C) using the CD34 obtained in step (B); + Hematopoietic vascular endothelial cells (CD34 + / CD43 - / CD45 - / CD184 - / CD73 - The method may further comprise a step of selecting a cell population containing the target cell.

[0077] CD34 + The cell population containing hematopoietic vascular endothelial cells can be separated from the cell population containing hematopoietic vascular endothelial cells by known methods, such as flow cytometry, magnetic cell separation, etc. By using the cell population containing hematopoietic vascular endothelial cells thus selected in the culture of step (1), it becomes possible to produce precursor T cells with higher efficiency.

[0078] The cell population containing T cell precursors produced by the production method of the present invention is a CD34 + The cell population is a cell population induced from T cells. The proportion (cell number) of T precursor cells contained in the cell population containing T precursor cells is, for example, 5% or more, preferably 15% or more, more preferably 25% or more, even more preferably 35% or more, and still more preferably 45% or more, and the upper limit is, for example, 100% or less.

[0079] Furthermore, the precursor T cell inducer of the present invention can contain the same components as those used in the aforementioned production method of the present invention. The precursor T cell inducer of the present invention can induce the differentiation of precursor T cells by using it in the above-mentioned production method.

[0080] The present invention further provides a culture medium for differentiating T cells precursors and a kit for differentiating T cells precursors. The culture medium and kit contain the same components as those in the production method of the present invention described above. In one aspect of the present invention, the kit for differentiating T cells precursors contains a suitable solid phase (e.g., a cell culture support such as a cell culture vessel, beads, a membrane, or a slide glass) to which fibronectin or a fragment thereof, and / or DLL4 are immobilized. In one aspect of the present invention, fibronectin or a fragment thereof, and / or DLL4 may be already immobilized to a suitable solid phase, or may be designed to be immobilized to a suitable solid phase upon use.

[0081] The precursor T cells contained in the cell population obtained by the production method of the present invention may be precursor T cells into which an exogenous gene has been introduced.

[0082] A "foreign gene" is a gene introduced from the outside to cause precursor T cells to express a desired protein, and can be selected appropriately depending on the intended use of the precursor T cells.

[0083] The foreign gene may be a foreign gene encoding a receptor. For example, such a foreign gene may be a gene for expressing a chimeric antigen receptor (CAR), a T cell receptor (TCR), a synthetic T cell receptor and antigen receptor (STAR), or a chimeric TAC (T cell antigen coupler) receptor. The foreign genes may be, for example, a gene for expressing a CAR and a gene for expressing a cytokine and / or a chemokine. Similar to common or known CARs, the CAR expressed by a cell is basically composed of peptides at each of the following sites linked via a spacer as necessary: ​​(i) an antigen recognition site (e.g., a single-chain antibody, a ligand, a peptide, etc.) that recognizes a cell surface antigen of a cancer cell; (ii) a cell membrane-spanning domain; and (iii) a signal transduction domain that induces T cell activation. Other exogenous genes include suicide genes (iCas9, HSV-TK, etc.), cytokines (interleukins, chemokines, etc.), and the like.

[0084] The means for introducing a foreign gene into cells is not particularly limited, and various known or common means can be used. Typically, the foreign gene is introduced into cells using an expression vector and expressed. The expression vector may be linear or circular, and may be a non-viral vector such as a plasmid, a viral vector, or a transposon-based vector. The cells into which the foreign gene is introduced are not particularly limited, and may be at any stage of differentiation, for example, pluripotent stem cells (particularly iPS cells), CD34 + Examples include T cells and T cell precursors.

[0085] The technique for introducing an expression vector into cells can be an appropriate one depending on the embodiment. For example, the expression vector can be introduced into cells by known methods such as viral infection, calcium phosphate, lipofection, microinjection, and electroporation. The expression vector can be prepared in a form suitable for use in each technique by known means or using a commercially available kit (according to its instructions).

[0086] The expression vector can be introduced into cells by viral infection. Examples of viral vectors include retroviral vectors, lentiviral vectors, adenoviral vectors, and adeno-associated viral vectors. When using these viral vectors, a vector containing a desired foreign gene and a packaging vector (plasmid) of each virus are transfected into host cells using a corresponding commercially available kit to produce a recombinant virus, and then the resulting recombinant virus is used to infect cells.

[0087] When there are multiple foreign genes, all of the foreign genes may be contained in a single expression vector, all of the foreign genes may be contained in separate expression vectors, or some of the multiple foreign genes may be contained in a single expression vector and the rest may be contained in separate expression vectors.When multiple foreign genes are contained in a single expression vector, the order in which the foreign genes are arranged from upstream to downstream is not particularly limited.

[0088] The foreign gene can be composed of a nucleic acid (polynucleotide) having a base sequence encoding the amino acid sequence of the desired protein or polypeptide. Those skilled in the art can design and prepare an expression vector capable of expressing the desired protein (polypeptide) in a cell. The nucleic acid contained in the expression vector can be prepared by chemical DNA synthesis or prepared as cDNA (cloning).

[0089] In addition to a foreign gene, an expression vector may contain sequences such as a promoter, a terminator, an enhancer, an initiation codon, a stop codon, a polyadenylation signal, a nuclear localization signal (NLS), and a multiple cloning site (MCS), as necessary. The expression vector may further comprise a reporter gene (e.g., a gene encoding a fluorescent protein of each color), a drug selection gene (e.g., a kanamycin resistance gene, an ampicillin resistance gene, a puromycin resistance gene), a suicide gene (e.g., a diphtheria A toxin, herpes simplex thymidine kinase (HSV-TK), carboxypeptidase G2 (CPG2), carboxylesterase (CA), cytosine deaminase (CD), cytochrome P450 (cyt-450), deoxycytidine kinase (dCK), nitroreductase (NR), purine nucleoside phosphorylase (PNP), thymidine phosphorylase (TP), varicella-zoster virus thymidine kinase (VZV-TK), xanthine-guanine phosphoribosyltransferase (XGPRT), inducible caspase 9 (inducible caspase 9)), or a gene encoding a cytochrome P450 (cyt-450). The nucleic acid sequence may include a nucleic acid (base sequence) encoding a "functional gene" such as a gene encoding a nucleotide sequence of ...

[0090] The production method and T cell precursor inducer of the present invention make it possible to produce T cell precursors with high efficiency by using an aromatic hydrocarbon receptor antagonist in combination with an LSD1 degradation inducer.

[0091] A cell population containing T cell precursors produced by the production method of the present invention is useful for treating animals (particularly humans) with conditions requiring an increase in T cell count. A "condition requiring an increase in T cell count" refers to a condition in which the number of blood T cells is reduced compared to that of healthy animals (e.g., conditions following anticancer drug therapy and / or radiation therapy, acquired immune deficiency syndrome (AIDS)). Furthermore, T cell precursors produced by the production method of the present invention are useful in cell therapy aimed at, for example, recovering T cells due to thymic damage following radiation therapy. When using the T cell precursors in cell therapy, cells into which a desired gene has been introduced can also be used. Such cells can be used to treat genetic diseases (e.g., recombinase deficiency, recombinase regulatory gene deficiency, severe combined immunodeficiency (SCID)). Accordingly, the present invention provides a pharmaceutical (sometimes simply referred to herein as the "pharmaceutical of the present invention") (particularly, a cell transplantation therapeutic agent) containing T cell precursors produced by the above production method, and a cell therapy method using the T cell precursors. The T precursor cells produced by the production method of the present invention may be used for autologous transplantation or allogeneic transplantation. They may also be used in combination with other drugs. As shown in the Examples, the T precursor cells produced by the production method of the present invention have the property of engrafting in the thymus, differentiating into T cells, and then migrating into the blood.

[0092] When carrying out such cell therapy, in order to avoid rejection reactions, it is preferable that the subject from which the cells are isolated has an HLA type that matches that of the subject to which the T precursor cells are administered, and it is more preferable that the subject is the same as the subject to which the T precursor cells are administered.

[0093] The medicament of the present invention can be, for example, a medicament (anticancer drug) for treating and preventing cancers that correspond to cell surface antigens (cancer-specific antigens) of cancer cells targeted by CAR expressed by T precursor cells. Examples of cancers that can be targeted by the medicament of the present invention include adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma, undifferentiated cancer, large cell carcinoma, small cell carcinoma, skin cancer (e.g., melanoma, Merkel cell carcinoma), breast cancer, prostate cancer, bladder cancer, vaginal cancer, cervical cancer, head and neck cancer, uterine cancer, cervical cancer, liver cancer, kidney cancer, pancreatic cancer, spleen cancer, lung cancer, non-small cell lung cancer, tracheal cancer, bronchial cancer, colon cancer, rectal cancer, small intestine cancer, colon cancer, and stomach cancer. cancers such as esophageal cancer, gallbladder cancer, testicular cancer, ovarian cancer, fallopian tube cancer, and nasopharyngeal cancer; cancers of bone tissue, cartilage tissue, adipose tissue, muscle tissue, vascular tissue, and hematopoietic tissue; sarcomas such as chondrosarcoma, Ewing's sarcoma, rhabdomyosarcoma, malignant hemangioendothelioma, osteosarcoma, and soft tissue sarcoma; blastomas such as hepatoblastoma, medulloblastoma, nephroblastoma, neuroblastoma, pancreatoblastoma, pleuropulmonary blastoma, and retinoblastoma; germ cell tumors; lymphomas; leukemia, acute myeloid leukemia, and multiple myeloma. Preferred examples include cancer types that are sensitive to NK cells (melanoma, Merkel cell carcinoma, colon cancer, kidney cancer, breast cancer, ovarian cancer, fallopian tube cancer, cervical cancer, liver cancer, lung cancer, non-small cell lung cancer, head and neck cancer, small intestine cancer, prostate cancer, bladder cancer, rectal cancer, pancreatic cancer, Ewing's sarcoma, rhabdomyosarcoma, nasopharyngeal cancer, esophageal cancer, biliary tract cancer, neuroblastoma, osteosarcoma, acute myeloid leukemia, multiple myeloma, lymphoma, leukemia, etc.).

[0094] When the pharmaceutical agent of the present invention is used for cancer treatment, it can be used in combination with known anticancer drugs, such as alkylating agents such as cyclophosphamide, bendamustine, ifosfamide, and dacarbazine; antimetabolites such as pentostatin, fludarabine, cladribine, methotrexate, 5-fluorouracil, 6-mercaptopurine, and enocitabine; molecular targeted drugs such as rituximab, cetuximab, and trastuzumab; kinase inhibitors such as imatinib, gefetinib, erlotinib, afatinib, dasatinib, sunitinib, and trametinib; Examples of such agents include proteasome inhibitors such as bortezomib; calcineurin inhibitors such as cyclosporine and tacrolimus; anticancer antibiotics such as idarubicin, doxorubicin, and mitomycin C; plant alkaloids such as irinotecan and etoposide; platinum preparations such as cisplatin, oxaliplatin, and carboplatin; hormone therapy drugs such as tamoxifen and bicaludamide; and immunosuppressants such as interferon, nivolumab, and pembrolizumab.

[0095] The medicament of the present invention has low toxicity and can be administered safely. The medicament of the present invention can be prepared as an oral / parenteral formulation by mixing an effective amount of a cell population containing T cell precursors with a pharmaceutically acceptable carrier according to known means. The medicament of the present invention is usually prepared as a parenteral formulation such as an injection, suspension, or infusion. Parenteral administration methods include intravenous, intraarterial, intramuscular, intraperitoneal, and subcutaneous administration. Examples of pharmaceutically acceptable carriers include solvents, bases, diluents, excipients, soothing agents, buffers, preservatives, stabilizers, suspending agents, isotonic agents, surfactants, and solubilizing agents.

[0096] The dosage of the medicament of the present invention can be determined appropriately depending on various conditions such as the patient's weight, age, sex, symptoms, etc. For example, the medicament of the present invention is usually administered in a single dose in an amount of 1×10 cells. 4 ~1 x 10 10 pieces, preferably 1 x 10 5 ~1 x 10 9 pieces, more preferably 5×10 6 ~5 x 10 8The medicament of the present invention may be administered once or multiple times. The medicament of the present invention may be in a known form suitable for parenteral administration, such as an injection or infusion. The medicament of the present invention may also contain physiological saline, phosphate-buffered saline (PBS), a culture medium, etc., in order to stably maintain the cells. Examples of the culture medium include, but are not limited to, RPMI, AIM-V, and X-VIVO10. Furthermore, the medicament may contain a pharmaceutically acceptable carrier (e.g., human serum albumin), a preservative, etc., for the purpose of stabilization. The medicament of the present invention is intended to be used in mammals, including humans.

[0097] As used in this specification and claims, singular terms include plurals and plural terms include the singular, unless the context otherwise requires. Thus, singular articles (e.g., "a," "an," "the," etc. in English) should be understood to include the plural concept, unless otherwise specified.

[0098] The present invention will be described in more detail below with reference to examples, but the present invention is not limited to these examples.

[0099] Example 1 Induction / Separation of Cell Populations Containing HECs As a cell population containing hematopoietic endothelial cells (HECs), a cell population was used, which was obtained by differentiating iPS cells (Ff-I01s04 strain: derived from peripheral blood mononuclear cells of a healthy individual, or Ff-WJc513 strain: derived from umbilical cord blood mononuclear cells of a healthy individual) provided by the Center for iPS Cell Research and Application, Kyoto University, according to a known method (for example, the method described in Cell Reports 2 (2012) 1722-1735 and WO 2017 / 221975).

[0100] Specifically, 1 × 10 Ff-I01s04 or Ff-WJc513 strains were cultured on an ultra-low adhesion treated 6-well plate. 6The cells were seeded at 1000 cells / well (Day 0) and cultured in EB medium (StemPro34 supplemented with 10 μg / ml human insulin, 5.5 μg / ml human transferrin, 5 ng / ml sodium selenite, 2 mM L-glutamine, 45 mM α-monothioglycerol, and 50 μg / ml ascorbic acid 2-phosphate) supplemented with 50 ng / ml BMP4, 50 ng / ml bFGF, 50 ng / ml VEGF, and 2 μM SB431542 under hypoxic conditions (5% O). 2 ) for 4 days (Day 4). Subsequently, the cells were cultured for another 4 days in a medium supplemented with 50 ng / ml bFGF, 50 ng / ml VEGF, and 50 ng / ml SCF (Day 8), to obtain a floating cell population containing HECs. The floating cell population containing HECs was stained with the following antibody set (Table 1). As shown in Figure 1, HECs were stained with CD14 - / CD235a - / CD34 + / CD43 - / CD184 - / CD73 - The cells were sorted using a BD FACS AriaFusion.

[0101]

[0102] Example 2 Differentiation of a Cell Population Containing HECs into a Cell Population Containing ProT Cells The HEC-containing cell population isolated by the method described above was seeded onto a 6-well plate coated with RetroNectin (RN; Takara Bio Inc.) and Fc-tagged recombinant human delta-like 4 (DLL4-Fc; Sino Biological) at 22,500 cells per well. The plate was prepared under the conditions of 5 μg / ml RN and 5 μg / ml DLL4-Fc concentrations. The basal medium used for culture was ProT medium (IMDM-Glutamax supplemented with 0.5% recombinant human albumin (Recombmin Elite, Albumedix), 10 μg / ml human insulin, 5.5 μg / ml human transferrin, 6.7 ng / ml sodium selenite, 2 μg / ml ethanolamine, 55 μM 2-mercaptoethanol, 20 U / ml penicillin-streptomycin, 0.1% polyvinyl alcohol (Sigma-Aldrich), and 50 μg / ml ascorbic acid 2-phosphate) containing 100 ng / ml recombinant human (rh) stem cell factor (SCF, R&D systems), 100 ng / ml rh Fms-like tyrosine. The cells were cultured for 12 days with the addition of kinase 3 ligand (Flt3L, PeproTech), 100 ng / ml rh thrombopoietin (TPO, PeproTech), 100 ng / ml rh interleukin 7 (IL-7, PeproTech), 10 ng / ml rh interleukin 6 (IL-6, PeproTech), 10 ng / ml rh interleukin 3 (IL-3, PeproTech), and 1 μM StemReginin-1 (SR1, Calbiochem). The obtained cells were collected by pipetting, stained with the following antibody set, and then analyzed for CD144 using a flow cytometer (FACS Aria Fusion, BD Bioscience). + / CD34 + / CD7 + It was confirmed that a cell population containing proT cells was induced (Figure 2).

[0103]

[0104] [Example 3] Promotion of pro-T cell differentiation by co-addition of SR1 and UM171 35 nM UM171 (Selleck Chemicals) was further added to the culture conditions of Example 2, and culture was carried out for 12 days. The obtained cells were recovered by pipetting, and subjected to antibody staining with the antibody set shown in Table 2. Then, CD144 was detected using a flow cytometer (FACS Aria Fusion, BD Bioscience). + / CD34 + / CD7 + The induction efficiency of precursor T cells (proT cells) was evaluated using SR1 and UM171. As a result, a cell population containing a high proportion of proT cells was induced when SR1 and UM171 were co-added (Figure 3).

[0105] [Example 4] In vivo engraftment evaluation of cell populations containing proT cells and confirmation of T cells in the blood. 2-day-old neonatal NOD.Cg-Prkdc scid Il2rg tm1Wjl 1.5 × 10 cells of the cell population containing T cell precursors induced from iPS cells in Example 2 or 3 were injected into a mouse 1 / SzJ (NSG) mouse (Jackson Laboratories Japan, Ltd.). 6 The cells were suspended in 30 μl of administration solution (10 μl D-PBS(-), 10 μl of 250 μg / ml anti-human / mouse IL-7 antibody (M25, Bio X Cell), and 10 μl of 50 μg / ml rhIL-7) and transplanted into the liver. The thymus was collected 4 weeks after administration, and blood was collected 8 and 12 weeks after administration to evaluate the presence of human CD45-positive T cells.

[0106] In the treated group, human CD45 was detected in the thymus. + / CD3 + / αβTCR + / CD4 + / CD8a + CD4 + CD8 + Double positive cells were confirmed. In addition, CD45 was detected in blood samples taken 8 and 12 weeks after transplantation using the cells induced by the method of Example 3. + / CD3 + / αβTCR+ / CD4 + / CD8a - CD4 + Single positive cells and CD45 + / CD3 + / αβTCR + / CD4 - / CD8a + CD8 + The presence of a single positive cell was confirmed (Figure 4). When the cells induced by the methods of Examples 2 and 3 were compared, the cells induced by the co-addition of UM171 showed higher thymus engraftment ability (Figure 5).

[0107] Example 5 Production of CAR-pro T Cells and In Vivo Anticancer Activity To evaluate the chimeric antigen receptor (CAR)-specific antitumor effect in vivo, a CAR against CD19, a B cell tumor antigen, was transduced into the differentiated cells using a lentiviral vector during the process of inducing differentiation from a cell population containing HECs to a cell population containing pro T cells. The lentiviral vector was added to the culture on day 7 after the start of differentiation induction. Four days after gene transduction (day 12 after the start of differentiation induction), the cultured cells were recovered and subjected to antibody staining with the antibody set listed in Table 3, followed by expression analysis using a flow cytometer. The results confirmed that pro T cells expressing CAR could be produced ( Figure 6 ).

[0108]

[0109] Two-day-old neonatal NOD.Cg-Prkdc scid Il2rg tm1Wjl 1.5 × 10 cells of the cell population containing CAR-expressing proT cells prepared as described above were injected into a mouse 1 / SzJ (NSG) mouse (Jackson Laboratories Japan, Ltd.). 6Each mouse was suspended in 30 μl of administration solution (10 μl D-PBS(-), 10 μl of 250 μg / ml anti-human / mouse IL-7 antibody (M25, Bio X Cell), and 10 μl of 50 μg / ml rhIL-7) and transplanted into the liver. Blood was collected weekly from 7 weeks after administration, stained with the antibody set shown in Table 3, and then expression analysis was performed using a flow cytometer to evaluate the presence of human CD45-positive CAR-T cells. In addition, 8 weeks after administration, 1 × 10 cells per mouse were transplanted with the CD19-expressing B cell tumor line NALM-6. 5 After intravenous administration, luciferase luminescence was monitored to evaluate the antitumor effect.

[0110] As a result, in the CAR-expressing proT cell transplant group, CD19CAR was detected in the blood. + / CD45 + / CD3 + / αβTCR + The presence of NALM-6 cells was confirmed (Figure 7). Furthermore, in individuals in which CAR-T cells were detected in the blood, luminescence from NALM-6 was not detected, and tumor growth was suppressed in these individuals (Figure 8).

[0111] This application is based on Japanese Patent Application No. 2023-91294 filed on June 2, 2023, the contents of which are incorporated in their entirety herein.

Claims

1. A method for producing a cell population containing T cell precursors, comprising the steps of: (1) activating CD34 in the presence of an aromatic hydrocarbon receptor antagonist and an LSD1 degradation inducer; + Culturing a cell population comprising the cells.

2. The method of claim 1, wherein the aromatic hydrocarbon receptor antagonist is StemRegenin-1 (SR1).

3. The method of claim 1, wherein the LSD1 degradation inducer is UM171.

4. The step (1) comprises the step of: mutating CD34 in the presence of fibronectin or a fragment thereof, and / or Delta like 4 (DLL4). + The method of claim 1, which is a step of culturing cells.

5. The step (1) comprises the step of: activating CD34 in the presence of at least one selected from the group consisting of stem cell factor (SCF), interleukin-3 (IL-3) and interleukin-6 (IL-6). + The method according to claim 4, which comprises culturing the cells.

6. CD34 + The cells are CD34 + / CD43 - / CD184 - / CD73 - The method of claim 1, which is a cell.

7. CD34 + The method of claim 1 , wherein the cell population comprising the cells is derived from induced pluripotent stem cells.

8. The method of claim 1, wherein the T cell precursor comprises an exogenous gene encoding a receptor.

9. A cell population containing T cell precursors obtained by the method of claim 1.

10. A pharmaceutical comprising a cell population containing the T cell precursors described in claim 9.

11. The pharmaceutical composition according to claim 10, which is a preventive and / or therapeutic drug for cancer.

12. A T cell precursor inducer comprising an aryl hydrocarbon receptor antagonist and an LSD1 degradation inducer.

13. The method of claim 12, wherein the aryl hydrocarbon receptor antagonist is SR1.

14. The agent according to claim 12, wherein the LSD1 degradation inducer is UM171.

15. The agent according to claim 12, further comprising fibronectin or a fragment thereof, and / or DLL4.

16. The agent according to claim 15, further comprising at least one member selected from the group consisting of SCF, IL-3 and IL-6.

17. A method for preventing and / or treating cancer, comprising administering a cell population containing the T cell precursor described in claim 9 to a subject in need thereof.

18. A cell population comprising the T cell precursor of claim 9 for use in the prevention and / or treatment of cancer.

19. Use of a cell population comprising the T cell precursor described in claim 9 in the manufacture of a medicament for preventing and / or treating cancer.

Citation Information

Patent Citations

  • Method for producing induced pluripotent stem cell

    JP2008283972A

  • Human pluripotent stem cell induced from human tissue-originated undifferentiated stem cell after birth

    JP2008307007A

  • Gripping device

    JP2023091294A

  • Hair Rollers

    US20080236610A1

  • Nuclear reprogramming factor and induced pluripotent stem cells

    US20090047263A1